We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Vertex Pharmaceuticals (VRTX) Advances While Market Declines: Some Information for Investors
Read MoreHide Full Article
Vertex Pharmaceuticals (VRTX - Free Report) closed the latest trading day at $402.70, indicating a +0.84% change from the previous session's end. This change outpaced the S&P 500's 0.43% loss on the day. At the same time, the Dow lost 0.07%, and the tech-heavy Nasdaq lost 0.9%.
Shares of the drugmaker witnessed a loss of 14.25% over the previous month, trailing the performance of the Medical sector with its loss of 7.03% and the S&P 500's loss of 1.98%.
Investors will be eagerly watching for the performance of Vertex Pharmaceuticals in its upcoming earnings disclosure. The company's upcoming EPS is projected at $4, signifying a 4.76% drop compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $2.77 billion, indicating a 10.18% increase compared to the same quarter of the previous year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $0.42 per share and revenue of $10.88 billion, indicating changes of -97.24% and +10.28%, respectively, compared to the previous year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Vertex Pharmaceuticals. These revisions typically reflect the latest short-term business trends, which can change frequently. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 4.36% lower. Vertex Pharmaceuticals is holding a Zacks Rank of #3 (Hold) right now.
Looking at its valuation, Vertex Pharmaceuticals is holding a Forward P/E ratio of 956.53. This represents a premium compared to its industry's average Forward P/E of 23.98.
It's also important to note that VRTX currently trades at a PEG ratio of 78.4. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. As of the close of trade yesterday, the Medical - Biomedical and Genetics industry held an average PEG ratio of 1.69.
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 59, this industry ranks in the top 24% of all industries, numbering over 250.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Vertex Pharmaceuticals (VRTX) Advances While Market Declines: Some Information for Investors
Vertex Pharmaceuticals (VRTX - Free Report) closed the latest trading day at $402.70, indicating a +0.84% change from the previous session's end. This change outpaced the S&P 500's 0.43% loss on the day. At the same time, the Dow lost 0.07%, and the tech-heavy Nasdaq lost 0.9%.
Shares of the drugmaker witnessed a loss of 14.25% over the previous month, trailing the performance of the Medical sector with its loss of 7.03% and the S&P 500's loss of 1.98%.
Investors will be eagerly watching for the performance of Vertex Pharmaceuticals in its upcoming earnings disclosure. The company's upcoming EPS is projected at $4, signifying a 4.76% drop compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $2.77 billion, indicating a 10.18% increase compared to the same quarter of the previous year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $0.42 per share and revenue of $10.88 billion, indicating changes of -97.24% and +10.28%, respectively, compared to the previous year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Vertex Pharmaceuticals. These revisions typically reflect the latest short-term business trends, which can change frequently. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 4.36% lower. Vertex Pharmaceuticals is holding a Zacks Rank of #3 (Hold) right now.
Looking at its valuation, Vertex Pharmaceuticals is holding a Forward P/E ratio of 956.53. This represents a premium compared to its industry's average Forward P/E of 23.98.
It's also important to note that VRTX currently trades at a PEG ratio of 78.4. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. As of the close of trade yesterday, the Medical - Biomedical and Genetics industry held an average PEG ratio of 1.69.
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 59, this industry ranks in the top 24% of all industries, numbering over 250.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.